Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$521M |
| 2 |
Nike
NKE
|
+$509M |
| 3 |
Micron Technology
MU
|
+$439M |
| 4 |
Super Micro Computer
SMCI
|
+$435M |
| 5 |
Broadcom
AVGO
|
+$329M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$5.31B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.89B |
| 3 |
Amazon
AMZN
|
+$1.48B |
| 4 |
Microsoft
MSFT
|
+$1.07B |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$904M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93% |
| 2 | Technology | 2.38% |
| 3 | Consumer Discretionary | 1.03% |
| 4 | Financials | 0.75% |
| 5 | Healthcare | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
10851
CALL
Amprius Technologies
AMPX
$1.54B
| $116K | ﹤0.01% |
91,300
-92,900
| -50% | -$152K |
|
10852
CALL
Abeona Therapeutics
ABEO
$345M
| $116K | ﹤0.01% |
27,300
-11,200
| -29% | -$57.1K |
|
10853
Outlook Therapeutics
OTLK
$156M
| $116K | ﹤0.01% |
+15,678
| New | +$126K |
|
|
ONCT
10854
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $116K | ﹤0.01% |
15,206
+5,012
| +49% | +$43.2K |
|
10855
PUT
Claros Mortgage Trust
CMTG
$233M
| $115K | ﹤0.01% |
+14,400
| New | +$122K |
|
10856
Ooma
OOMA
$633M
| $115K | ﹤0.01% |
+11,615
| New | +$92.3K |
|
|
GENE
10857
DELISTED
Genetic Technologies Ltd.
GENE
| $115K | ﹤0.01% |
77,303
+42,707
| +123% | +$96.1K |
|
|
TOKE
10858
DELISTED
Cambria Cannabis ETF
TOKE
| $115K | ﹤0.01% |
20,138
+5,236
| +35% | +$32.3K |
|
|
OMGA
10859
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $115K | ﹤0.01% |
55,322
+22,102
| +67% | +$52.1K |
|
10860
Spruce Power Holding Corp
SPRU
$36.2M
| $114K | ﹤0.01% |
31,361
+2,517
| +9% | +$9.3K |
|
10861
Douglas Elliman
DOUG
$169M
| $114K | ﹤0.01% |
98,638
+29,570
| +43% | +$37.2K |
|
10862
Cellectar Biosciences
CLRB
$24M
| $114K | ﹤0.01% |
1,525
+930
| +156% | +$89.2K |
|
|
QIPT
10863
DELISTED
Quipt Home Medical
QIPT
| $114K | ﹤0.01% |
+35,489
| New | +$127K |
|
10864
CALL
Asure Software
ASUR
$259M
| $114K | ﹤0.01% |
13,600
-51,800
| -79% | -$391K |
|
10865
PUT
LENSAR
LNSR
$104M
| $114K | ﹤0.01% |
25,300
+15,300
| +153% | +$59K |
|
|
CMCM
10866
CALL
Cheetah Mobile
CMCM
$92.8M
| $114K | ﹤0.01% |
28,600
+17,300
| +153% | +$79.3K |
|
|
NVRO
10867
CALL
DELISTED
NEVRO CORP.
NVRO
| $114K | ﹤0.01% |
13,500
-12,900
| -49% | -$138K |
|
|
RPC
10868
CALL
Ridgepost Capital
RPC
$960M
| $114K | ﹤0.01% |
13,400
-800
| -6% | -$6.38K |
|
10869
Immuneering
IMRX
$337M
| $114K | ﹤0.01% |
+88,756
| New | +$146K |
|
|
LGO
10870
CALL
Largo
LGO
$75.4M
| $114K | ﹤0.01% |
+61,400
| New | +$107K |
|
10871
CEL-SCI Corp
CVM
$28.1M
| $114K | ﹤0.01% |
3,263
-19,037
| -85% | -$811K |
|
10872
PUT
Relay Therapeutics
RLAY
$4.26B
| $113K | ﹤0.01% |
+17,400
| New | +$119K |
|
10873
PUT
Sight Sciences
SGHT
$463M
| $113K | ﹤0.01% |
17,000
-7,500
| -31% | -$44.3K |
|
10874
INNOVATE Corp
VATE
$106M
| $113K | ﹤0.01% |
18,747
+17,075
| +1,021% | +$113K |
|
|
GRCE
10875
Grace Therapeutics
GRCE
$45.4M
| $113K | ﹤0.01% |
37,793
+1,143
| +3% | +$3.45K |
|
Similar funds
Jeff Yass's Q2 2024 Portfolio in Review
As of Q2 2024, Jeff Yass held 13,638 positions worth $537B, down 6.7% from $576B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass's Q2 2024 filing shows 1,591 new, 4,593 increased, 5,607 reduced and 1,726 closed positions. Its largest new stake was NextEra Energy 7.299% Corporate Units: 2,575,000 shares worth $127M. The largest sale was NVIDIA, an estimated $5.31B.
By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q2 2024 buy was NextEra Energy 7.299% Corporate Units: 2,575,000 shares worth $127M.
- Jeff Yass added most to Vanguard FTSE Developed Markets ETF in Q2 2024, an estimated $521M increase.
- Jeff Yass's biggest Q2 2024 reduction was NVIDIA, cutting an estimated $5.31B.
- Jeff Yass fully exited iShares MSCI USA Quality Factor ETF in Q2 2024, selling an estimated $26.2M.
- Jeff Yass's ten largest holdings make up 26% of its $537B portfolio in Q2 2024.
- Jeff Yass opened 1,591 new positions and closed 1,726 in Q2 2024.
- Jeff Yass's portfolio value fell 6.7% quarter-over-quarter to $537B.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.